Stay updated on High Dose Cytarabine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision was updated from v3.2.0 to v3.3.2, with no substantive changes to the study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding lapse disclaimer from the page. This does not alter the study details or how a user would interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedUpdated Study Record Dates show the last update posted on 2024-09-25 and a revised record status. The core study design details appear unchanged.SummaryDifference0.4%

- Check70 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference2%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0. No other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2, indicating a minor release; the 'Back to Top' link was removed as a small UI adjustment with no impact on core content.SummaryDifference0.1%

Stay in the know with updates to High Dose Cytarabine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.